Takeaways RJVA-002 uses gene therapy to deliver GLP-1 and GIP directly from pancreatic beta cells in a nutrient-responsive way. Preclinical studies in obese mice show up to 30% body weight loss and improved…
Takeaways Once-monthly MariTide led to up to 17.5% weight loss in 52 weeks, with minimal regain after stopping treatment. The drug combines GLP-1 and glucagon receptor activity, offering fat burn and appetite suppression…
Takeaways Emerging GPCR-targeted therapies could offer oral, appetite-modifying weight-loss options with fewer GI side effects. GSBR-1290 shows real human efficacy (~5–7% weight loss) and convenience, while BRP highlights non-incretin, central-acting alternatives in preclinical…
Takeaways Controlled mitochondrial uncouplers like HU6 are in early human trials and show promise for reducing liver fat and body adiposity while preserving lean mass. Organ-targeted and prodrug delivery systems enhance safety by…
Takeaways Dual‑pathway therapies deliver stronger, longer-lasting fat loss while preserving lean mass. AI‑guided dosing promises smarter personalization, improving adherence and real‑world outcomes. The oral and injectable co‑agonist amycretin marks a breakthrough in obesity…
Ecnoglutide (XW003): The Next-Generation GLP-1 Analog Redefining Weight-Management Therapy For clinics developing truly integrated medical weight loss programs, a once-weekly GLP-1 analog called ecnoglutide is emerging as the most advanced “biased-signaling” option yet.…
Takeaways Gene-editing therapies targeting obesity now enter first-in-human trials, aiming to deliver one-time, lasting results. Programs like Verve-102 and MC4R editors focus on reducing fat while preserving or improving metabolic health. These curative…
Takeaways Dual-Path Weight Loss cuts fat dramatically while preserving lean muscle, solving the key drawback of GLP-1 monotherapy. Phase 2b BELIEVE data show 22 % total-weight loss with 93 % fat reduction; a…
Takeaways Semaglutide significantly improves liver inflammation, fibrosis, and weight loss in patients with MASH. The ESSENCE Phase 3 trial demonstrated superior outcomes for semaglutide over placebo in multiple clinical measures. Integrating semaglutide into…
Takeaways Oral GLP-1 receptor agonists offer a needle-free alternative that can improve adherence and expand access to obesity treatment. Medications like semaglutide and orforglipron work by reducing appetite, slowing digestion, and boosting insulin…